

USSN 10/500,936

REMARKS

The present application was originally filed with 18 Claims. In the present Restriction Requirement, the Examiner has restricted the Claims into 35 Groups, as indicated below:

- I. Group I contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 7 in the sequence of subtilisin BPN';
- II. Group II contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 23 in the sequence of subtilisin BPN';
- III. Group III contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 26 in the sequence of subtilisin BPN';
- IV. Group IV contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 28 in the sequence of subtilisin BPN';
- V. Group V contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 29 in the sequence of subtilisin BPN';
- VI. Group VI contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 30 in the sequence of subtilisin BPN';
- VII. Group VII contains Claims 1-12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 31 in the sequence of subtilisin BPN';
- VIII. Group VIII contains Claims 1-3, 5-12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 47 in the sequence of subtilisin BPN';
- IX. Group IX contains Claims 1-3, 6, 12-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 61 in the sequence of subtilisin BPN';

USSN 10/500,936

- X. Group X contains Claims 1-3, 5, 6, 9, 12-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 66 in the sequence of subtilisin BPN';
- XI. Group XI contains Claims 1-3, 6, 9-12, and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 69 in the sequence of subtilisin BPN';
- XII. Group XII contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 73 in the sequence of subtilisin BPN';
- XIII. Group XIII contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 82 in the sequence of subtilisin BPN';
- XIV. Group XIV contains Claims 1-9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 85 in the sequence of subtilisin BPN';
- XV. Group XV contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 88 in the sequence of subtilisin BPN';
- XVI. Group XVI contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 90 in the sequence of subtilisin BPN';
- XVII. Group XVII contains Claims 1-3, 5-9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 92 in the sequence of subtilisin BPN';
- XVIII. Group XVIII contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 93 in the sequence of subtilisin BPN';
- XIV. Group XIV contains Claims 1-3, 5-9, and 12-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 105 in the sequence of subtilisin BPN';
- XX. Group XX contains Claims 1-3, 5-9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 113 in the sequence of subtilisin BPN';

USSN 10/500,936

- XXI. Group XXI contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 139 in the sequence of subtilisin BPN';
- XXII. Group XXII contains Claims 1-12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 148 in the sequence of subtilisin BPN';
- XXIII. Group XXIII contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 149 in the sequence of subtilisin BPN';
- XXIV. Group XXIV contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 150 in the sequence of subtilisin BPN';
- XXV. Group XXV contains Claims 1-3, 5-9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 151 in the sequence of subtilisin BPN';
- XXVI. Group XXVI contains Claims 1-3, 6-9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 174 in the sequence of subtilisin BPN';
- XXVII. Group XXVII contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 178 in the sequence of subtilisin BPN';
- XXVIII. Group XXVIII contains Claims 1-3, 5-9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 200 in the sequence of subtilisin BPN';
- XXIX. Group XXIX contains Claims 1-3, 5-12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 201 in the sequence of subtilisin BPN';
- XXX. Group XXX contains Claims 1-3, 6, and 9-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 203 in the sequence of subtilisin BPN';
- XXXI. Group XXXI contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 231 in the sequence of subtilisin BPN';

USSN 10/500,936


- XXXII. Group XXXII contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 233 in the sequence of subtilisin BPN';
- XXXIII. Group XXXIII contains Claims 1-3, 6, and 9-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 258 in the sequence of subtilisin BPN';
- XXXIV. Group XXXIV contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 267 in the sequence of subtilisin BPN'; and
- XXXV. Group XXXII contains Claims 1-6, 9, 12 and 15-18, drawn in part to a subtilisin modified by an amino acid substitution at a position corresponding to position 273 in the sequence of subtilisin BPN'.

Applicant hereby elects the Claims in Group III (Claims 1-6, 9, 12 and 15-18) without traverse. Applicant also reserves the right to prosecute the originally filed, broader, and/or similar Claims in one or more additional applications.

Should the Examiner have any questions regarding this application, he is encouraged to call the undersigned.

Respectfully submitted,

Dated: 23 December 2005


Kamrin T. MacKnight
Reg. No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel.: (650) 846-5838
Fax: (650) 845-6504